Halozyme Therapeutics, Inc. vs. Novavax Inc
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| HALO | NVAX | |
|---|---|---|
| Market Cap | $12.15 billion | $1.49 billion |
| Revenue (TTM) | $1.66 billion | $413.80 million |
| Net Income (TTM) | $413.60 million | $-247,730,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | NVAX | |
|---|---|---|
| P/E Ratio | 31.17 | — |
| Price / Book | 84.65 | -7.83 |
| Price / Sales | 7.30 | 3.61 |
NVAX leads on 2 of 2 valuation factors.
Profitability
| HALO | NVAX | |
|---|---|---|
| Net Margin | 24.86% | -59.87% |
| Return on Equity | 288.13% | 129.90% |
HALO leads on 2 of 2 profitability factors.
Dividend
| HALO | NVAX | |
|---|---|---|
| Dividend Yield | — | 14.09% |
HALO and NVAX split the dividend factors evenly.
Risk & Sentiment
| HALO | NVAX | |
|---|---|---|
| Short Interest | 9.79% | 25.98% |
HALO leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, NVAX overview, NVAX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.